Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

de Claro, R. Angelo, McGinn, Karen, Kwitkowski, Virginia, Bullock, Julie, Khandelwal, Aakanksha, Habtemariam, Bahru, Ouyang, Yanli, Saber, Haleh, Lee, Kyung, Koti, Kallappa, Rothmann, Mark, Shapiro, Marjorie, Borrego, Francisco, Clouse, Kathleen, Chen, Xiao Hong, Brown, Janice, Akinsanya, Lara, Kane, Robert, Kaminskas, Edvardas, Farrell, Ann, Pazdur, Richard·2012·Clinical Cancer Research

Abstract

The U.S. Food and Drug Administration (FDA) describes the accelerated approval of brentuximab vedotin for patients with relapsed Hodgkin lymphoma and relapsed systemic anaplastic large-cell lymphoma (sALCL). FDA analyzed the results of two single-arm trials, enrolling 102 patients with Hodgkin lymphoma and 58 patients with sALCL. Both trials had primary endpoints of objective response rate (ORR) and key secondary endpoints of response duration and complete response (CR) rate. For patients with Hodgkin lymphoma, ORR was 73% (95% CI, 65–83%); median response duration was 6.7 months, and CR was 32% (95% CI, 23–42%). For patients with sALCL, ORR was 86% (95% CI, 77–95%), median response duration was 12.6 months, and CR was 57% (95% CI, 44–70%). The most common adverse reactions were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting. FDA granted accelerated approval of brentuximab vedotin for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplantation (ASCT) or after failure of at least two prior multiagent chemotherapy regimens in patients who are not ASCT candidates, and for the treatment of patients with sALCL after failure of at least one prior multiagent chemotherapy regimen. Clin Cancer Res; 18(21); 5845–9. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-1803

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 210

Metadata

Authors
de Claro, R. A., McGinn, K., Kwitkowski, V., Bullock, J., Khandelwal, A., Habtemariam, B., Ouyang, Y., Saber, H., Lee, K., Koti, K., Rothmann, M., Shapiro, M., Borrego, F., Clouse, K., Chen, X. H., Brown, J., Akinsanya, L., Kane, R., Kaminskas, E., Farrell, A., & Pazdur, R.
Venue
Clinical Cancer Research
Published
2012-11-01
Volume
18
Issue
21
Pages
5845-5849
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2126879510
Cited by
210
References
0
FWCI
14.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-1803
The paper
de Claro, R. A., McGinn, K., Kwitkowski, V., Bullock, J., Khandelwal, A., Habtemariam, B., Ouyang, Y., Saber, H., Lee, K., Koti, K., Rothmann, M., Shapiro, M., Borrego, F., Clouse, K., Chen, X. H., Brown, J., Akinsanya, L., Kane, R., Kaminskas, E., . . . Pazdur, R. (2012). U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-1803

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.